Yep, thanks for the clarification. Not trying to downplay the results for ABT but I do wonder how effectively a 5-drug HCV combo will be able to compete with what I imagine will ultimately be at least a few 3-drug HCV combos (and hopefully, as a Medivir long, one of them containing simeprevir).
Market Data 
Markets 
AI
